{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    9,
    10,
    11,
    13,
    14,
    16,
    19,
    30,
    31,
    32,
    38,
    45,
    48,
    51,
    52
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Eligibility Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1",
        "sectionTitle": "Eligibility Criteria",
        "description": "Reference to eligibility criteria from the overall study design section"
      },
      {
        "id": "ref_2",
        "name": "Safety Monitoring Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.11, 3.14, 3.15",
        "sectionTitle": "Operations Manual",
        "description": "Reference to clinical laboratory test results, ECGs, and vital signs in Appendix F"
      },
      {
        "id": "ref_3",
        "name": "Study Schematic Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Figure 1",
        "sectionTitle": "Study Design Schematic",
        "description": "Internal link to the study design visual representation"
      },
      {
        "id": "ref_4",
        "name": "Study Procedures Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Section 3",
        "sectionTitle": "Operations Manual",
        "description": "Reference to detailed study procedures in Appendix F"
      },
      {
        "id": "ref_5",
        "name": "Prohibited Medications Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.3",
        "sectionTitle": "Prohibited Medications and Therapy",
        "description": "Reference for discontinuing medications to meet eligibility"
      },
      {
        "id": "ref_6",
        "name": "Dose Conversion Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.2",
        "sectionTitle": "Discussion of Study Design",
        "description": "Reference to conversion algorithm based on Phase 1 studies"
      },
      {
        "id": "ref_7",
        "name": "Infusion Site Evaluation Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.6",
        "sectionTitle": "Operations Manual",
        "description": "Reference to the Infusion Site Evaluation scale in Appendix F"
      },
      {
        "id": "ref_8",
        "name": "Follow-up Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.7",
        "sectionTitle": "Follow-Up After Subject Discontinuation",
        "description": "Reference for additional information on post-treatment activities"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "The Screening Period may be extended up to a total of 90 days for extenuating circumstances, e.g., supply constraints.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Figure 1",
        "pageNumber": 11
      },
      {
        "id": "annot_2",
        "text": "The Monitoring Period can occur any time before V3, as long as it lasts for 6 consecutive days.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Figure 1",
        "pageNumber": 11
      },
      {
        "id": "annot_3",
        "text": "As allowed by local regulations, subjects will receive the PKG-watch following Screening Visit 1 (V1) and will be required to wear it during the Monitoring Period.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Figure 1",
        "pageNumber": 11
      },
      {
        "id": "annot_4",
        "text": "Software version 'DL.v01.05' is installed on the pumps.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 9",
        "pageNumber": 33
      },
      {
        "id": "annot_5",
        "text": "Subjects enrolled under protocol v6.0 (or after) will use the Neria Guard infusion set at the start of enrollment.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 9",
        "pageNumber": 33
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "7.0",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "11 February 2021",
        "description": "A 52-Week, open-label, single-arm study to evaluate the safety and tolerability of 24-hour daily exposure of CSCI of ABBV-951",
        "amendmentNumber": "7"
      }
    ],
    "summary": {
      "referenceCount": 8,
      "annotationCount": 5,
      "versionCount": 1
    }
  }
}